Benzinga's M&A Chatter for Thursday February 25, 2016

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday February 25, 2016: Sanofi in Talks to Acquire PTC Therapeutics The Rumor:
Sanofi SA SNY is in talks to acquire PTC Therapeutics, Inc. PTCT, according to a source familiar with the matter as reported by Benzinga on Thursday. The two companies began talks earlier this week after PTC said it received a Refuse to File notice from the FDA regarding Translarna, the source said. Société Générale is said to be assisting PTC Therapeutics in the negotiations. A Sanofi spokesperson declined comment on the report. PTC Therapeutics did not respond to request for comment. PTC Therapeutics closed at $51.36 on Thursday, up $0.18. Energy Transfer Said to be Considering Pulling Out of Williams Deal The Rumor:
Energy Transfer Equity ETE has considered offering a one-time payment more than $2 billion to Williams Cos WMB to back out of its acquisition deal, according sources as reported by the NY Times Dealbook on Thursday. Since ETE agreed to buy Williams for $32.9 billion, in September 2015, shares of the two companies have lost a combines $37 billion in market value. The dramatic decline was due to the collapse in the price of oil and also on investor concerns over the deal. Energy Transfer Equity shares fell 5% on Thursday, to close at $6.80. Williams share fell 3.61% to close at $16.03. Rouse Properties to be Acquired by an Affiliate of Brookfield Asset Management for $18.25/Share in Cash The Deal:
Rouse Properties, Inc. RSE announced Thursday it has agreed to be acquired by an affiliate of Brookfield Asset Management Inc. BAM for $18.25 per share in cash. The transaction is valued at approximately $2.8 billion. Brookfield's had originally offered $17.00 per share for Rouse. The transaction is expected to close during Q3 of 2016. Rouse closed at $18.40 on Thursday, up 3.66%. Mckesson to Acquire Vantage Oncology And Biologics in Two Transactions Totaling $1.2B The Deal:
McKesson Corporation MCK announced Thursday, that it has signed definitive agreements to acquire Vantage Oncology, LLC and Biologics, Inc. The two transactions, valued at $1.2 billion, are expected to close in Q1 of Fiscal 2017. Mckesson closed at $155.37 on Thursday, up $0.70.